DYNE THERAPEUTICS INC. - COMMON STOCK

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

02 Jul 2025 13:01:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

30 Jun 2025 18:45:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

30 Jun 2025 13:05:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

30 Jun 2025 13:01:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

17 Jun 2025 04:00:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET

16 Jun 2025 13:05:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress

05 Jun 2025 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

08 May 2025 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

24 Apr 2025 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

15 Apr 2025 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Apr 2025 13:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

20 Mar 2025 13:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

20 Mar 2025 13:10:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

16 Mar 2025 16:00:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

11 Mar 2025 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

27 Feb 2025 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

14 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

03 Feb 2025 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

21 Jan 2025 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

10 Jan 2025 03:30:00 By Nasdaq GlobeNewswire